Uni-Bio Science Group Limited (0690.HK) HKSE
Currency In HKD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In HKD
Address
No. 20 Science Park East Avenue
Sha Tin,
Hong Kong
Phone
852 3102 3232
Sector
Healthcare
Industry
Biotechnology
Employees
487
First IPO Date
November 12, 2001
| Name | Title | Pay | Year Born |
| Zhi Gang Zhao | Chief Executive Officer & Executive Director | 1.51M | 1965 |
| Dawei Chen EMBA | Executive Vice Chairman of the Board | 378,000 | 1970 |
| Ya Lei Wen | Chief Operating Officer & Executive Director | 1.72M | 1961 |
| Kingsley Leung AHKIoD | Executive Chairman of the Board | 3.16M | 1987 |
| Wen Du An | Head of Distribution Sales | 0 | 1983 |
| Wei Tian | Head of HR & Administration Department | 0 | 1984 |
| Jing Li | Head of R&D Department | 0 | 1980 |
| Wenming Chen | Head of the Medical & Registration Department | 0 | 1987 |
| Kai Du | Head of Financial & Financial Controller | 0 | 1981 |
| Yujing Hong | Head of Strategic Development & Emerging Business | 0 | N/A |
| Shan Yu | Head of R&D | 0 | N/A |
Uni-Bio Science Group Limited functions as an investment holding enterprise primarily engaged in the research, development, manufacturing, and distribution of biological and chemical pharmaceutical products aimed at treating human health conditions across the People's Republic of China. Its existing product range features GeneTime, a prescribed biological medication for promoting wound healing; GeneSoft, an EGF-based eye drop used to address dry eye syndrome, corneal damage, and to assist post-operative recovery; Pinup, a voriconazole tablet designed to combat severe fungal infections; and Bokangtai, a mitiglinide tablet prescribed for managing Type 2 diabetes, alongside Boshutai, an oral anti-diabetic drug tailored for patients with pre-diabetes. Additionally, the company is progressing with the development of several investigational prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; rhPTH 1-34 (Uni-PTH), targeting osteoporosis in postmenopausal women; and Uni-GLP, a GLP-1 agonist offering a non-insulin treatment alternative for Type 2 diabetes. The firm was established in 2001 and its headquarters are located in Sha Tin, Hong Kong.